Articles

Lilly hopes Elanco unit becomes a cash cow

Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco’s productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.

Read More

Chao exit hurts drug development industry

Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.

Read More

Harlan Labs names new CEO

The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.

Read More

To attack costs, Lilly accelerates R&D

With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.

Read More

Lilly looks to autoimmune drugs

Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.

Read More